TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. - Wikidata - awgldk - TriplyDB

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

http://www.wikidata.org/entity/Q30399437

about

Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.Immune checkpoint blockade in infectious diseases.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer.Informatics for cancer immunotherapy.Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.Trial watch: Immune checkpoint blockers for cancer therapy.Recombinant Poliovirus for Cancer Immunotherapy.CD96 expression determines the inflammatory potential of IL-9-producing Th9 cells.CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.Introduction to checkpoint inhibitors and cancer immunotherapy.Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.Coming of Age: CD96 Emerges as Modulator of Immune Responses.Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.Next generation immune-checkpoints for cancer therapy.Not All Immune Checkpoints Are Created Equal Human Bone Marrow-Resident Natural Killer Cells Have a Unique Transcriptional Profile and Resemble Resident Memory CD8 T Cells

P2860

Q39429983-361A20AA-C0BD-4D0D-868C-9C5A88930CFF Q40082486-A4E18398-3747-4623-80B9-A5DA998EFDAF Q41921732-3BDF4BA8-87EC-4188-B644-F2B6B35511E7 Q46971015-A89FBAEE-B21B-44F1-8E29-94F0EACEB4C8 Q47144850-AAC283B4-678E-4C46-8463-A7B585C29108 Q47290509-A7B07418-4D50-4304-968E-76B84E60EA60 Q47301132-E66842F9-C501-4070-B93A-0E556E9E61D0 Q47393365-E2AEF2D7-497A-4DAF-AD45-4E2C9FD1B604 Q48508304-F4E886C3-BA92-4D2E-B7AF-07A90C724943 Q52659614-8286E5B4-9D2A-45A5-A24C-D72F825009BB Q52714314-B5159CE8-4B90-4646-8255-BC1A5D944FF1 Q54212829-4B5B3F83-95D5-4412-B6D3-C7FC8B45A5EC Q54657348-AF00ED58-002B-48B8-9EF2-2A140015FDE7 Q55008075-4E0792D8-D5B5-46B4-B322-26B4C22E5A5E Q55026846-03C325B5-7767-4763-935D-9D1DDBC6FB6E Q55262681-602895B5-F3C1-4592-BBAB-97452432FD8C Q55316580-B065B1F5-483A-48F4-888F-1B4B3EB99684 Q55383705-4FF77DC4-F5CD-4CC0-919A-B3339195326F Q56889626-7733A34C-BF31-43D6-A2FA-6DF43C35B00D Q58719549-95A1CAE4-6D7E-449D-A2A2-CD10B13F2B94

P2860

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

http://www.wikidata.org/entity/Q30399437

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

@ast

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

@en

type

label

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

@ast

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

@en

prefLabel

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

@ast

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

@en

P1433

Q30399437-86859AAA-3114-4ACD-9A29-D79E1F2867C7

P1476

Q30399437-18A7C06E-73E2-41BE-A004-18F3D712E8A3

P2093

Q30399437-84934683-38E3-4B56-A19E-D4FBA438F6D9

Q30399437-A191BD2B-EDE3-4AE7-90C7-9467B40C1118

Q30399437-FFC49E6A-05AC-4C84-A209-53F9824234C0

P2860

Q30399437-01552B05-7DCC-46B2-8559-39E74ADDDAFF

Q30399437-089CB954-9AA0-42E7-9F91-189A46F6161C

Q30399437-1427E2DE-6B06-4F6E-ABF2-A362D9E41811

Q30399437-1B6D7EE2-D415-4720-83FD-56E1BE6F283E

Q30399437-203BD592-C48F-4265-BE80-82D36B35A433

Q30399437-20492B24-4DD0-41B9-8E04-3A48B7502A97

Q30399437-213CFD0B-7D42-4C49-80FB-82569AF09CB4

Q30399437-28B54DE0-BDEC-4852-AFE0-E12BC3D7F204

Q30399437-2AA20774-CA9B-4DD0-89D3-B0C40441236A

Q30399437-2AA8F469-78FC-40D4-B710-45948378B032

P304

Q30399437-B91DC4CD-8F38-4CDE-8A55-0221FC84C878

P31

Q30399437-0868CBEF-F39F-4C1D-AB00-C7710C8900EC

P356

Q30399437-CD23A559-4D0F-4A0B-A111-753EF25944EA

P433

Q30399437-C155F5D3-8BDE-4651-819C-BF2BBA70E31E

P478

Q30399437-497F74C7-9AE6-4D30-BA5E-A87ADFD2FFC6

P50

Q30399437-8386F617-0E30-46A8-8D9F-A634AD023803

P577

Q30399437-3CADB494-65F0-4D1C-9D17-E436CB54B26D

P698

Q30399437-9FD68E40-5032-45AE-89C1-04DFAF2E5C2A

P921

Q30399437-0F5578D7-9BD6-46EC-8263-42D82567BE5C

P356

P1433

Immunological Reviews

P1476

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

@en

P2093

Ana C Anderson

http://www.w3.org/2001/XMLSchema#string

Sema Kurtulus

http://www.w3.org/2001/XMLSchema#string

William C Dougall

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

Cancer-Associated Myeloid Regulatory Cells

Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice

Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering

Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome

P304

112-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMR.12518

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

276

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28258695

http://www.w3.org/2001/XMLSchema#string

P921